PHARMAESSENTIA CORP
BiotechPHARMAESSENTIA CORP is a biotechnology company focused on Infectious Disease, Oncology, Immunology.
FDA Novel Drug Designations
(2021)See 1 novel approval →
PHARMAESSENTIA CORP at a Glance
- Fast trial execution (23 months median completion)
Upcoming FDA Decisions
Full Calendar →PHARMAESSENTIA CORP's Key Drugs
PHARMAESSENTIA CORP's core commercial portfolio centers on BESREMI, spanning Infectious Disease and Oncology — its most strategically important drugs approved in the last 15 years.
PHARMAESSENTIA CORP's Recent FDA Approvals
New NDA/BLA approvals for PHARMAESSENTIA CORP over the last two years — novel drugs only, excluding generics and label supplements.
PHARMAESSENTIA CORP's Therapeutic Areas
PHARMAESSENTIA CORP's approved drugs and pipeline span 3 therapeutic areas, led by Infectious Disease and Oncology. Weighted by commercial stage — approved drugs count most, then late-stage trials.
PHARMAESSENTIA CORP's Top Competitors
PHARMAESSENTIA CORP's closest competitors by therapeutic-area and drug-target overlap include Pfizer, AbbVie, and Johnson & Johnson. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
PHARMAESSENTIA CORP Pipeline Snapshot
PHARMAESSENTIA CORP has 8 active clinical programs from ClinicalTrials.gov — 2 Phase 3, 1 Phase 2 and 5 Phase 1.
Phase 3 Readout Calendar Pro
2 Phase 3 trials with confidence-graded primary completion dates.
Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • BESREMI leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Infectious Disease pipeline focus
- • 2 Phase 3 readouts tracked
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 2/5 completed
- • Speed: 23 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 2021-11-12
- Latest
- 2024-04-29
- Applications
- 1
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges